Combining human antisera to human leukocyte antigens, HIVgp120 and 70 kDa heat shock protein results in broadly neutralizing activity to HIV-1

AIDS

Volumn 22, Issue 11, 2008, Pages 1267-1276

  Babaahmady, Kaboutar ^a   Bergmeier, Lesley A ^a   Lehner, Thomas ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

HIV 1; HLA I; HLA II; Neutralizing antibodies

Indexed keywords

ANTISERUM; CHEMOKINE RECEPTOR CCR5; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 120 ANTIBODY; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 70 ANTIBODY; HLA ANTIBODY; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 1 ANTIBODY; HLA ANTIGEN CLASS 2; HLA ANTIGEN CLASS 2 ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; HLA ANTIGEN; IMMUNOGLOBULIN G;

ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BLOOD ANALYSIS; CD4+ T LYMPHOCYTE; CLADISTICS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HLA SYSTEM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; MALE; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VIRUS INHIBITION; VIRUS NEUTRALIZATION; CELL CULTURE; IMMUNOLOGY; PATHOGENICITY; PHYSIOLOGY; VIROLOGY; VIRULENCE;

ANTIBODIES, MONOCLONAL; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HIV ENVELOPE PROTEIN GP120; HIV-1; HLA ANTIGENS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; IMMUNE SERA; IMMUNOGLOBULIN G; VIRULENCE;

EID: 49849099242     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328304b3a6     Document Type: Article

References (57)

1. Tremblay MJ, Fortin J-F, Cantin R. The acquisition of host-encoded proteins by nascent HIV-1. Immunol Today 1998; 19:346-351.
2. Arthur LA, Bess JW Jr, Sowder RC II, Benveniste RE, Mann DL, Chermann J-C, Henderson LE. Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science 1992; 258:1935-1938.
3. Gurer C, Cimarelli A, Luban J. Specific incorporation of heat shock protein 70 family members into primate lentiviral virions. J Virol 2002; 76:4666-4670.
4. O'Connor DH, Allen TM, Vogel TU, Jing P, DeSouza IP, Dodds E, et al. Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat Med 2002; 8:493-499.
5. Barouch DH, Kunstman J, Kuroda MJ, Schmitz JE, Santra S, Peyerl FW, et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 2002; 415:335-339.
6. Lehner T, Shearer GM, Hackett CJ, Schultz A, Sharma OK. Workshop Summary. Alloimmunization as a strategy for vaccine design against HIV/AIDS. AIDS Res Hum Retroviruses 2000; 16:309-313.
7. Stott EJ. Anticell antibody in macaques. Nature 1991; 353:393.
8. Arthur LO, Bess JW Jr, Urban RG, Strominger JJ, Morton WR, Mann DL, et al. Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus. J Virol 1995; 69:3117-3124.
9. Stott JE, Almond N, West W, Kent K, Cranage MP, Rudd E. Protection against simian immunodeficiency virus infection of macaques by cellular or viral antigens. Neuvieme Colloque Des Cent Gardes 1994; 219-225.
10. Chan WL, Rodgers A, Grief C, Almond N, Ellis S, Flanagan B, et al. Immunization with class I human histocompatibility leukocyte antigen can protect macaques against challenge infection with SIVmac-32H. AIDS 1995; 9:223-228.
11. Polyanskaya N, Sharpe S, Cook N, Leech S, Banks J, Dennis M, et al. Antimajor histocompatibility complex antibody responses to simian B cells do not protect macaques against SIVmac infection. AIDS Res Hum Retroviruses 1997; 13:923-931.
12. Pinto LA, Sharpe S, Cohen DI, Shearer G. Alloantigen-stimulated anti-HIV activity. Blood 1998; 92:3346-3354.
13. Wang Y, Tao L, Mitchell E, Bravery C, Berlingieri P, Armstrong P, et al. Allo-immunization elicits CD8+ T cell-derived chemokines, HIV suppressor factors and resistance to HIV infection in women. Nat Med 1999; 5:1004-1009.
14. Wang Y, Underwood J, Vaughan R, Harmer A, Doyle C, Lehner T. Allo-immunization elicits CCR5 antibodies, SDF-1 chemokines, and CD8-suppressor factors that inhibit transmission of R5 and X4 HIV-1 in women. Clin Exp Immunol 1999; 129:493-501.
15. Peters B, Whittall T, Babaahmady K, Gray K, Vaughan R, Lehner T. Effect of heterosexual intercourse on mucosal alloimmunisation and resistance to HIV-1 infection. Lancet 2004; 363: 518-524.
16. Agnew LL, Kelly M, Howard J, Jeganathan S, Batterham M, French MA, et al. Altered lymphocyte heat shock protein 70 expression in patients with HIV disease. AIDS 2003; 17:1985-1988.
17. Babahmady K, Oehlmann W, Singh M, Lehner T. Inhibition of HIV-1 infection of human CD4+ T cells by microbial HSP70 and the peptide epitope 407-426. J Virol 2007; 81:3354-3360.
18. Burton DR, Stanfield RL, Wilson IA. Antibody vs. HIV in a clash of evolutionary titans. Proc Natl Acad Sci USA 2005; 102: 14943-14948.
19. Scanlan CN, Pantophlet R, Wormald MR, Saphire EO, Stanfield R, Wilson IA, et al. The broadly neutralizing antihuman immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha 1-2 mannose residues on the outer face of gp120. J Virol 2002; 76:306-321.
20. Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, Steindl F, Katinger H. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2001; 17:1757-1765.
21. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001; 75:10892-10905.
22. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, et al. Protection of macaques against pathogenic simian/ human immunodeficiency virus 89.6P by passive transfer of neutralizing antibodies. J Virol 1999; 73:4009-4018.
23. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000; 6:207-210.
24. Parren PW, Marx PA, Hessell AI, Luckay AJ, Harouse A, Cheng-Mayer J, et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001; 75:8340-8347.
25. Veazey RS, Shattock RJ, Pope MJ, Kirijan C, Jones J, Hu Q, et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 2003; 9:343-346.
26. Baba T, Liska V, Hoffmann-Lehmann R, Vlasak J, Xu W, Ayehunie S, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000; 6:200-206.
27. Ferrantelli F, Hoffmann-Lehmann R, Rasmussen RA. Postexposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. AIDS 2003; 17:301-309.
28. Hoffmann-Lehmann R, Vlasak J, Rasmussen RA, Smith BA, Baba TW, Liska V, et al. Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J Virol 2001; 75:7470-7480.
29. Hoffmann-Lehmann R, Vlasak I, Rasmussen RA, Jiang S, Li PL, Baba TW, et al. Postnatal pre and postexposure passive immunization strategies: protection of neonatal macaques against oral simian-human immunodeficiency virus challenge. J Med Primatol 2002; 31:109-119.
30. Muster T, Steindl F, Purtscher M, Hayes D, Louder MK, Brown CR, et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type I. J Virol 1993; 67:6642-6647.
31. Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, Rudd PM, et al. Crystal structure of a neutraslizing human IgG against HIV-1: a template for vaccine design. Science 2001; 293:1155-1159.
32. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998; 280:1884-1888.
33. Zwick MB, Parren PW, Saphire EO, Church S, Wang M, Scott JK, et al. Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120. J Virol 2003; 77:5863-5876.
34. Kwong PD, Wyatt R, Majeed S, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure 2000; 8:1329-1339.
35. Montefiori DC. Neutralizing antibodies take a swipe at HIV in vivo. Nat Med 2005; 11:593-594.
36. Haynes BF, Fleming J, St-Clair EW, Katinger H, Stiegler G, Kunert R, et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005; 308: 1906-1908.
37. Morin-Papunen L, Tiilikainen A, Hartikainen-Sorri A-L. Maternal HLA immunization during pregnancy: presence of anti HLA antibodies in half of multigravidous women. Med Microbiol 1984; 62:323-325.
38. Pockley AG, Shepherd J, Corton JM. Detection of heat shock protein 70 (hsp70) and anti-Hsp70 antibodies in the serum of normal individuals. Immunol Invest 1998; 27:367-377.
39. Hunter-Lavin C, Davies EL, Bacelar MMFVG, Marshall MJ, Andrew SM, Williams JHH. Hsp70 release from peripheral blood mononuclear cells. Biomed Biophys Res Commun 2004; 324:511-517.
40. Dhillon AK, Donners H, Pantophlet R, Johnson WE, DeckerJM, Shaw GM, et al. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1 infected donors. J Virol 2007; 81:6548-6562.
41. Haynes BF, Montefiori DC. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev Vaccines 2006; 5:579-595.
42. Li X, Migueles SA, Welcher B, Svehla K, Phogat A, Louder MK, et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 2007; 13:1032-1034.
43. Stamatos NM, Mascola JR, Kalyanaraman VS, Louder MK, Frampton LM, Birx DL, VanCott TC. Neutralizing antibodies from the sera of human immunodeficiency virus type 1 infected individuals bind to monomeric gp120 and oligomeric gp140. J Virol 1998; 72:9656-9667.
44. Beirnaert E, De Zutter S, Janssens W, van der Groen G. Potent broad cross-neutralizing sera inhibit attachment of primary HIV-1 isolates (groups M and O) to peripheral blood mononuclear cells. Virology 2001; 281:305-314.
45. Cham F, Zhang PF, Heyndrickx L, Bouma P, Zhong P, Katinger H, et al. Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity. Virology 2006; 347:36-51.
46. Quinnan GV Jr, Zhang PF, Fu DW, Dong M, Alter HJ. Expression and characterization of HIV type 1 envelope protein associated with a broadly reactive neutralizing antibody response. AIDS Res Hum Retrovir 1999; 15:561-570.
47. Finzi A, Orthwein A, Mercier J, Cohen EA. Productive human immunodeficiency virus type 1 assembly takes place at the plasma membrane. J Virol 2007; 81:7476-7490.
48. Chappell TG, Welch WJ, Schlossman DM, Palter KB, Schlesinger MJ, Rothman JE. Uncoating ATPase is a member of the 70 kilodalton family of stress proteins. Cell 1996; 45:3-13.
49. Agostini I, Popov LS, Li J, Dubrovsky L, Hao T, Bukrinsky M. Heat-shock protein 70 can replace viral protein R of HOV-1 during nuclear import of the viral preintegration complex. Exp Eye Res 2000; 259:398-403.
50. Lordanskiy S, Zhao Y, Dubrovsky L, Lordanskaya T, Chen M, Liang D, Bukrinsky M. Heat shock protein 70 protects cells from cell cycle arrest and apoptosis induced by human immunodeficiency virus type 1 viral protein R. J Virol 2004; 78:9697-9704.
51. Gurer C, Hoglund A, Hoglund S, Luban J. ATPgS disrupts human immunodeficiency virus type 1 virion core integrity. J Virol 2005; 79:5557-5567.
52. Whittall T, Wang Y, Younson J, Kelly C, Bergmeier LA, Peters B, et al. Interaction between the CCR5 chemokine receptors and microbial HSP70. Eur J Immunol 2006; 36:2304-2314.
53. Blattman JN, Antia R, Sourdive DJD, Wang X, Kaech SM, Murali-Krishna K, et al. Estimating the precursor frequency of naïve antigen-specific CD8 T cells. J Exp Med 2002; 195:657-664.
54. Lehner T, Wang Y, Whittall T, McGowan E, Kelly CG, Singh M. Functional domains of HSP70 stimulate generation of cytokines and chemokines, maturation of dendritic cells and adjuvanticity. Biochem Soc Trans 2004; 32:629-632.
55. Wang Y, Kelly CG, Singh M, McGowan EG, Carrara A-S, Bergmeier LA, Lehner T. Stimulation of Th1-polarizing cytokines, C-C chemokines, maturation of dendritic cells and adjuvant function by the peptide binding fragment of heat shock protein 70. J Immunol 2002; 169:2422-2429.
56. Floto RA, MacAry PA, BonameJM, Mien TS, Kampmann B, Hair JR, et al. Dendritic cell stimulation by mycobacterial Hsp70 is mediated through CCR5. Science 2006; 314:454-458.
57. + T cells and dendritic cells. J Immunol 2007; 178:1671-1679.